NCT02643381

Brief Summary

Patients who are having problems breathing sometimes require placement of a breathing tube in their mouth and windpipe. The purpose of this breathing tube is to save the patient's life. It is common to give the patient a medication to sedate him or her before the breathing tube is placed. For patients who are gravely ill two medications are commonly used: etomidate or ketamine. Both medications have risks and benefits. Researchers at UT-Southwestern Medical Center and Parkland Memorial Hospital would like to do a study to figure out which one is better for our patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
801

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Jun 2016

Longer than P75 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 11, 2015

Completed
20 days until next milestone

First Posted

Study publicly available on registry

December 31, 2015

Completed
5 months until next milestone

Study Start

First participant enrolled

June 6, 2016

Completed
4.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2020

Completed
1 year until next milestone

Results Posted

Study results publicly available

December 15, 2021

Completed
Last Updated

December 15, 2021

Status Verified

November 1, 2021

Enrollment Period

4.5 years

First QC Date

December 11, 2015

Results QC Date

November 15, 2021

Last Update Submit

November 15, 2021

Conditions

Keywords

etomidateketamineendotracheal intubationanesthesia induction medications

Outcome Measures

Primary Outcomes (1)

  • Survival at Day 7

    Survival is defined as the number of participants survived at day 7 following emergency endotracheal intubation

    Day 7

Secondary Outcomes (7)

  • Survival at Day 28

    Day 28

  • Sequential Organ Failure Assessment (SOFA) Scores

    Day 1, Day 2, Day 3, Day 4

  • Duration of Mechanical Ventilation

    From time of documented insertion until the time of documented removal, assessed up to 28 days

  • Duration of Catecholamine Therapy

    From time of documented start of therapy until the time of documented end of therapy, assessed up to 28 days

  • Length of Stay in ICU

    Assessed up to 28 days

  • +2 more secondary outcomes

Study Arms (2)

Etomidate

EXPERIMENTAL

Patients randomized to this group will receive etomidate immediately prior to emergency endotracheal intubation.

Drug: EtomidateProcedure: Emergency Endotracheal IntubationDevice: Mechanical Ventilation

Ketamine

EXPERIMENTAL

Patients randomized to this group will receive ketamine immediately prior to emergency endotracheal intubation.

Drug: KetamineProcedure: Emergency Endotracheal IntubationDevice: Mechanical Ventilation

Interventions

Patients randomized to this group will receive etomidate immediately prior to emergency endotracheal intubation.

Etomidate

Patients randomized to this group will receive ketamine immediately prior to emergency endotracheal intubation.

Ketamine

Patients enrolled in the study will be endotracheally intubated. (A breathing tube will be placed into the patient's mouth and trachea). This procedure is being done as part of standard emergency care. Standard endotracheal tubes will be used. Our hospital uses primarily Mallinckrodt (TM) brand endotracheal tubes.

EtomidateKetamine

Patients enrolled in the study will be mechanically ventilated, using a standard ventilator used in our hospital. The mechanical ventilator is attached to the patient's endotracheal tube and helps sustain the patient's life. Our hospital uses several brands of mechanical ventilators.

EtomidateKetamine

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patient (male or female) requiring emergency endotracheal intubation.

You may not qualify if:

  • Children (\<18 years old).
  • Women who are known to be pregnant.
  • Any patient who has been previously randomized in the EvK Trial.
  • Patients who require endotracheal intubation without sedative medication. For example, patients in full cardiac arrest.
  • Patients with a known allergy to ketamine or etomidate.
  • Any individual wearing a MedAlert bracelet indicating that he/she has formally opted out of the EvK Trial.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Parkland Hospital

Dallas, Texas, 75235, United States

Location

Related Publications (2)

  • Matchett G, Ryan TJ, Sunna MC, Lee SC, Pepe PE; EvK Clinical Trial Group. Measuring the cost and effect of current community consultation and public disclosure techniques in emergency care research. Resuscitation. 2018 Jul;128:37-42. doi: 10.1016/j.resuscitation.2018.04.033. Epub 2018 Apr 30.

  • Matchett G, Gasanova I, Riccio CA, Nasir D, Sunna MC, Bravenec BJ, Azizad O, Farrell B, Minhajuddin A, Stewart JW, Liang LW, Moon TS, Fox PE, Ebeling CG, Smith MN, Trousdale D, Ogunnaike BO; EvK Clinical Trial Collaborators. Etomidate versus ketamine for emergency endotracheal intubation: a randomized clinical trial. Intensive Care Med. 2022 Jan;48(1):78-91. doi: 10.1007/s00134-021-06577-x. Epub 2021 Dec 14.

MeSH Terms

Conditions

Heart ArrestApnea

Interventions

EtomidateKetamineRespiration, Artificial

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesRespiration DisordersRespiratory Tract DiseasesSigns and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

ImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsCyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsAirway ManagementTherapeuticsResuscitationEmergency TreatmentRespiratory Therapy

Results Point of Contact

Title
Gerald Matchett
Organization
UT-Southwestern Medical Center

Study Officials

  • Gerald Matchett, MD

    University of Texas

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor of Medicine

Study Record Dates

First Submitted

December 11, 2015

First Posted

December 31, 2015

Study Start

June 6, 2016

Primary Completion

December 1, 2020

Study Completion

December 1, 2020

Last Updated

December 15, 2021

Results First Posted

December 15, 2021

Record last verified: 2021-11

Data Sharing

IPD Sharing
Will not share

Aggregate anonymous data will be published in accord with our IRB approval.

Locations